Equillium Q4 2022: $15.8M revenue from Ono deal, net income $2.8M; cash $71M into 2025

Equillium, Inc.

Revenue of $15.8M in Q4 2022 from Ono Pharmaceutical asset purchase agreement; no revenue in prior year period.
Net income of $2.8M ($0.08 per share) in Q4 2022 vs net loss of $10.6M in Q4 2021.
Full year 2022 net loss of $62.4M ($1.85 per share) vs $39.1M loss in 2021, including non-cash in-process R&D from Bioniz acquisition.
Cash, cash equivalents and short-term investments total $71.0M as of Dec 31, 2022; expected to fund operations into 2025.
Partnership with Ono for itolizumab: $26.4M upfront, up to $139M in milestones, and R&D funding.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Equillium, Inc. reported the quarter ended December 31, 2022 results: revenue $15.8 million.

Period: the quarter ended December 31, 2022
Revenue: $15.8 million
Result: reported results

Exact text from the filing

Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Equillium, Inc. reported the year ended December 31, 2022 results: revenue $15.8 million.

Period: the year ended December 31, 2022
Revenue: $15.8 million
Result: reported results

Exact text from the filing

Revenue for the fourth quarter and full year of 2022 was $15.8 million and was derived from the company’s asset purchase agreement with Ono.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Equillium, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-077853

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.